Financial Comparison: Palvella Therapeutics (PVLA) & Its Peers

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Palvella Therapeutics to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Palvella Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	3	0	3.00
Palvella Therapeutics Competitors	8083	21715	49485	1298	2.55

Palvella Therapeutics currently has a consensus price target of $41.00, indicating a potential upside of 105.00%. As a group, “Pharmaceutical preparations” companies have a potential upside of 237.26%. Given Palvella Therapeutics’ competitors higher probable upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its competitors.

Risk and Volatility

Palvella Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of 3.67, meaning that their average share price is 267% more volatile than the S&P 500.

Earnings & Valuation

This table compares Palvella Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.65
Palvella Therapeutics Competitors	$2.31 billion	$122.98 million	-6.01

Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.38%	-220.04%	-32.84%

Summary

Palvella Therapeutics competitors beat Palvella Therapeutics on 8 of the 13 factors compared.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.